{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:26:40Z","timestamp":1766158000073,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.urolonc.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T08:30:41Z","timestamp":1477470641000},"page":"39.e1-39.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Nicholas M.","family":"Donin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan J.","family":"Pantuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Kivlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Holldack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaella","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence I.","family":"Karsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence H.","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie S.","family":"Belldegrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Holden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.09.006_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"6 Suppl 1","key":"10.1016\/j.urolonc.2016.09.006_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.09.006_bib3","unstructured":"American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. Available from: http:\/\/ww.auanet.org\/education\/guidelines\/bladder-cancer.cfm [cited 22.01.16]"},{"key":"10.1016\/j.urolonc.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"issue":"6 Suppl 4","key":"10.1016\/j.urolonc.2016.09.006_bib7","first-page":"S199","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2016.09.006_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. the Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/ni.1733","article-title":"Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells","volume":"10","author":"Mancuso","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/092986707780059625","article-title":"The antitumoral mode of action of imiquimod and other imidazoquinolines","volume":"14","author":"Schon","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.urolonc.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.juro.2007.01.112","article-title":"Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder","volume":"177","author":"Smith","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib12","first-page":"3528","article-title":"Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine","volume":"52","author":"Sidky","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1442-2042.2010.02503.x","article-title":"Intravesical toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer","volume":"17","author":"Hayashi","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.juro.2012.11.150","article-title":"Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer","volume":"189","author":"Falke","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1464-410X.2010.10055.x","article-title":"Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs","volume":"108","author":"Arentsen","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.09.006_bib16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.09.006_bib17","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrurol.2013.153","article-title":"Toll-like receptors in urothelial cells\u2014targets for cancer immunotherapy","volume":"10","author":"LaRue","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib23","first-page":"CD006885","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","volume":"5","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2016.09.006_bib24","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.09.006_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.09.006_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"4 Suppl 11","key":"10.1016\/j.urolonc.2016.09.006_bib27","first-page":"S3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urolonc.2016.09.006_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","article-title":"Mitomycin C: mechanism of action, usefulness and limitations","volume":"1","author":"Verweij","year":"1990","journal-title":"Anticancer Drugs"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:17Z","timestamp":1761041357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916302745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1078143916302745"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.09.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}